Navigation Links
GlySure Secures $10.9 Million in Series C Financing Round
Date:1/9/2012

OXFORD, England, January 9, 2012 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced the close of its $10.9 million Series C financing round. GlySure will use this funding to complete clinical trials to supportregulatory approval in the United States and Europe.

The financing round was supported by Morningside Venture, as well as existing investors Amadeus Capital Partners, Chester Investments and Delta Partners. Since its foundation in May 2006, GlySure has secured a total of $19.5 million in venture capital funding.

"We are excited about the opportunity to support GlySure's regulatory trials," said Reenie McCarthy, representing Morningside Venture. "There is a significant unmet need for continuous glucose monitoring in critical care, and the results from GlySure's initial ICU trials show that the company is on track to deliver the performance and ease-of-use required to enable clinicians to effectively implement Tight Glycemic Control."

GlySure recently completed initialhuman use trials on over 90 intensive care patients. The trials demonstrated that the GlySure system can accurately measure blood glucose levels across the entire human physiological range for the duration of a patient's stay in the Intensive Care Unit(ICU).

"This new financing round recognizes not only the significant clinical results, but also the management team's capital efficiency and ability to cost effectively deliver a product with the potential to improve outcomes for over 8 million ICU patients annually," added Dr. Joey Mason, partner at Delta Partners and a director of GlySure.

"There have been over 100 publications demonstrating the ability of Tight Glycemic Control to improve outcomes and reduce cost in the ICU," said Chris Jones, GlySure CEO. "We are grateful for the support of our existing and new investors and look forward to completing our regulatory trials so that we can bring intensive care units a system that will allow them to deliver on the decade-long promise of Tight Glycemic Control."

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 16 employees. http://www.glysure.com.


'/>"/>
SOURCE GlySure
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
3. GeoVax Secures $10 Million Financing Commitment
4. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
5. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
6. ALung Secures $2.5 Million
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. EnzySurge, Maker of DermaStream(R) Secures US$2.5 Million in Private Capital
9. HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing
10. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
11. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):